Table 2.
AGREE Scores for Draft Clinical Decision Support Summaries
| Drug/genetic pair | Identified a priori or novel finding? | Domain 1 (Scope and Purpose) | Domain 3 (Rigour of Development) | Domain 4 (Clarity of Presentation) | Domain 5 (Applicability) | Overall mean ± SD quality score (averaged across reviewers) | Guideline recommended for clinical deployment? |
|---|---|---|---|---|---|---|---|
| asparaginase/rs6021191/rs17885382 | novel | 93.1 | 86.1 | 29.2 | 29.2 | 4.5±0.6 | Yes |
| capectabine/fluorouracil/DPYD | a priori | 98.1 | 96.3 | 96.3 | 88.9 | 7±0.0 | Yes |
| cisplatin/rs1872328 | novel | 88.9 | 81.9 | 37.5 | 41.7 | 4.5±0.6 | Yes |
| doxorubicin/rs1883112 | novel | 86.1 | 83.3 | 44.4 | 27.1 | 4.5±1.3 | Yes |
| doxorubicin/rs8187710 | novel | 86.1 | 83.3 | 44.4 | 33.3 | 4.5±1.3 | Yes |
| doxorubicin/rs13058338 | novel | 86.1 | 83.3 | 44.4 | 33.3 | 4.5±1.3 | Yes |
| irinotecan/UGT1A1*28 | a priori | 96.3 | 79.6 | 81.5 | 80.6 | 5.7±0.6 | Yes |
| lapatanib/HLA-DQA1*02:01 | novel | 91.7 | 90.3 | 38.9 | 33.3 | 4.3±1.0 | Yes |
| mercaptopurine/thioguanine/TPMT | a priori | 95.8 | 98.6 | 98.6 | 87.5 | 7±0.0 | Yes |
| sunitinib/rs307826 | novel | 93.1 | 80.6 | 41.7 | 60.4 | 4.5±1.3 | No |
| sunitinib/rs776746 | novel | 90.3 | 80.6 | 41.7 | 54.2 | 4.8±1.3 | Yes |
| tamoxifen/CYP2D6 | a priori | 100.0 | 98.1 | 87.0 | 88.9 | 6.3±0.6 | Yes |
| vincristine/rs924607 | novel | 100.0 | 97.2 | 76.4 | 68.8 | 5.8±1.3 | Yes |
| Overall mean ± SD scores | 92.7±5.1 | 87.6±7.4 | 58.6±25.1 | 55.9±24.6 | 5.2±1.0 |
SD=standard deviation